Latest advanced melanoma Stories
- Update from Advanced Breast Cancer and Melanoma Studies - Conference Call to be Hosted on Wednesday, June 3, 2009 at 11:00 am BRANFORD, Conn., May 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) today announced plans for three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO)...
- Updated Survival and Biomarker Data for Ipilimumab to be Presented - PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc.
Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's lead oncology product, in patients with advanced melanoma.
Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who had previously been treated.
- A serpent whose bite was fabled to produce intense thirst.